{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:29:23Z","timestamp":1790548163147,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","jada.ada.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.adaj.2025.11.015","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:17:20Z","timestamp":1769631440000},"page":"787-794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral mucositis secondary to datopotamab deruxtecan for advanced-stage cancer managed with cryotherapy after topical steroid failure"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-3391","authenticated-orcid":false,"given":"Paolo J.","family":"Fantozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6480-2625","authenticated-orcid":false,"given":"Stephen T.","family":"Sonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4364-5824","authenticated-orcid":false,"given":"John P.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-6000","authenticated-orcid":false,"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adaj.2025.11.015_bib1","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"29","key":"10.1016\/j.adaj.2025.11.015_bib2","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.adaj.2025.11.015_bib3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.adaj.2025.11.015_bib4","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.adaj.2025.11.015_bib5","first-page":"756","article-title":"US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan","volume":"33","author":"Rugo","year":"2025","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.adaj.2025.11.015_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adaj.2025.11.015_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"16 suppl","key":"10.1016\/j.adaj.2025.11.015_bib8","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","article-title":"SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study","volume":"41","author":"Fang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adaj.2025.11.015_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.adaj.2025.11.015_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cden.2007.10.002","article-title":"Management of oral mucositis in patients who have cancer","volume":"52","author":"Lalla","year":"2008","journal-title":"Dent Clin North Am"},{"issue":"10","key":"10.1016\/j.adaj.2025.11.015_bib12","first-page":"6061","article-title":"Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers","volume":"29","author":"Villa","year":"2021","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.adaj.2025.11.015_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s11606-007-0321-2","article-title":"Accuracy of the pain numeric rating scale as a screening test in primary care","volume":"22","author":"Krebs","year":"2007","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.adaj.2025.11.015_bib14","series-title":"AJCC Cancer Staging Manual","year":"2016"},{"issue":"8","key":"10.1016\/j.adaj.2025.11.015_bib15","first-page":"732","article-title":"Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device","volume":"33","author":"Zuniga","year":"2025","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.adaj.2025.11.015_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.adaj.2025.11.015_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106692","article-title":"Unsung oral toxicities of antibody drug conjugate","volume":"150","author":"Chirravur","year":"2024","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.adaj.2025.11.015_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbmt.2014.11.680","article-title":"Mammalian target of rapamycin inhibitor\u2013associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease","volume":"21","author":"Villa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.adaj.2025.11.015_bib19","first-page":"57","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.adaj.2025.11.015_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.adaj.2025.11.015_bib21","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.adaj.2025.11.015_bib22","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.adaj.2025.11.015_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41409-021-01512-6","article-title":"Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial","volume":"57","author":"Walladbegi","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817725006932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817725006932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:22:32Z","timestamp":1787296952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817725006932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0002817725006932"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2025.11.015","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral mucositis secondary to datopotamab deruxtecan for advanced-stage cancer managed with cryotherapy after topical steroid failure","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Dental Association. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}